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Abstract
The action of dopamine on the aggregation of the unstructured alpha-synuclein (a-syn) protein may be linked to the
pathogenesis of Parkinson’s disease. Dopamine and its oxidation derivatives may inhibit a-syn aggregation by non-covalent
binding. Exploiting this fact, we applied an integrated computational and experimental approach to find alternative ligands
that might modulate the fibrillization of a-syn. Ligands structurally and electrostatically similar to dopamine were screened
from an established library. Five analogs were selected for in vitro experimentation from the similarity ranked list of analogs.
Molecular dynamics simulations showed they were, like dopamine, binding non-covalently to a-syn and, although much
weaker than dopamine, they shared some of its binding properties. In vitro fibrillization assays were performed on these five
dopamine analogs. Consistent with our predictions, analyses by atomic force and transmission electron microscopy
revealed that all of the selected ligands affected the aggregation process, albeit to a varying and lesser extent than
dopamine, used as the control ligand. The in silico/in vitro approach presented here emerges as a possible strategy for
identifying ligands interfering with such a complex process as the fibrillization of an unstructured protein.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative movement
disorder, affecting an estimated four million people worldwide
[1,2]. It is characterized by the loss of the neuromelanin expressing
dopamine (DOP) neurons in the substantia nigra pars compacta and the
deposition of Lewy bodies in many of the cells remaining in this
region [3,4,5,6,7,8,9]. The major components of the Lewy bodies
are fibrillar aggregates of the alpha-synuclein protein (a-syn)
[6,10,11]. Thus, a-syn fibrillization and DOP metabolism are likely
to be linked to PD pathogenesis [11,12,13,14,15,16,17,18,19,20,21].
DOP and some derivatives (Figure 1), which may be present in
oxidizing conditions, form non-covalent and/or covalent adducts
with a-syn [21,22]. These molecules inhibit the conversion of a-syn
to mature fibrils, promoting instead, accumulation of oligomeric (or
protofibril) forms [23,24,25,26,27].
Recently, molecular dynamics (MD) simulations based on a-
syn’s nuclear magnetic resonance (NMR) structural ensemble [28]
in combination with biophysical methods, led some of us to
propose a structural basis for DOP non-covalent inhibition of a-
syn fibrillization [29]. This may be caused, at least in part, by 1)
the formation of nonspecific hydrophobic contacts between DOP
and its oxidation derivatives with the C-terminal; this includes the
125YEMPS
129 region, as in agreement with experimental evidence
[23,28] and 2) long-range electrostatic interactions with residues in
the NAC region which are involved in the fibrillization process
[29].
Molecules structurally and electrostatically similar to a given
ligand might provide similar structure/activity relationships [30].
We screened ligands structurally and electrostatically similar to
DOP (Figure 2) from the ligand.info meta-database [31]. The ability
of these ligands to bind to a-syn was then explored by MD
simulations. The ligands bound weaker to the protein than DOP.
Consistently, high-resolution atomic force microscopy (AFM) and
transmission electron microscopy (TEM) data showed that the
ligands affected a-syn fibril assembly, but to a lower extent than
DOP. Remarkably, the best analogs revealed the most inhibitory
effects upon protein aggregation in terms of fibril length and
quantity.
Results
Dopamine Mimics: Identification and Binding to a-Syn
We screened seventy molecules of the ligand.info database [31]
with the largest similarity with DOP and its oxidation derivatives
(Table S1). The similarity was quantified according to the
Tanimoto’s equations [32]. The ligands were docked onto the
six structural representatives of human a-syn in aqueous solution.
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9234The procedure was identical to that of previously reported [29],
except that a refined set of structures of a-syn were used (see
Material and Methods). The resulting complexes were ranked in
terms of the number of contacts with the
125YEMPS
129 region
known-to-be targeted by DOP [24,26,29]. Such ranking was used
only as a means to fast screen the ligands, and not to provide
structural predictions. In fact, there are severe limitations of this
procedure for an unstructured protein, as discussed by Slutzki et al
[33] Five commercially available ligands chosen randomly from
Table S1 and forming top ranking adducts (Figure 2), underwent
36 ns MD simulations in water solution (Table S2). The same
procedure was used for DOP and its derivatives (Figure 1).
DOP and its oxidation derivatives bound for 69% or more of
their time to a-syn (the criteria used to identify bound complexes
are described in Materials and Methods) and bound preferentially
to the target
125YEMPS
129 region, similarly to previous MD
simulations [29]. As found previously [29], they did not form
specific interactions with the target region (Table S2). Moreover,
they interacted with one or both negative residues (E83 and E61)
of the NAC region (Table 1), a region known to be involved in the
fibrillization of the protein. DOP-E83 interaction might play a role
in the observed inhibition of fibrillization by DOP, as suggested
experimentally [29].
Three of the screened ligands (6-aminoindole, 5-hydroxyindole,
2-amino-4-tert-butylphenol) interacted significantly with a-syn (and
in particular with the
125YEMPS
129 region), although to a lesser
extent than most dopamine derivatives (Table 1). In addition, they
formed much weaker stabilizing electrostatic interactions with E61
and/or E83 (Table 1).
We have also studied several binding regions of ligands other
than the target region. The results are provided in Table S3,
where the contacts are listed for those adducts in which the ligands
bind to regions other than the target region for more than 50% of
their time.
The other two ligands, tyramine and 4-(2-aminoethylaniline),
bound much less to a-syn (albeit still interacting with the
125YEMPS
129 region), with almost no stabilizing interactions with
the two residues (E61 and E83) of NAC region.
As in the case of DOP, all the ligands did not form specific
interactions with any residues in the
125YEMPS
129 region (Table S2).
Based on these results, we propose that: (i) the DOP mimics may
interfere with the fibrillization of a-syn, although to a lesser extent
than DOP and (ii) the ligands, that show the strongest binding to
a-syn, i.e 6-aminoindole, and 5-hydroxyindole, and 2-amino-4-
tert-butylphenol may have the strongest effect on the fibrillization
of a-syn. We next proceeded to perform in vitro assays to test these
two predictions.
In Vitro Fibrillization Assays
Human a-syn was produced and purified as described previously
[34], with some modifications. Protein analysis by SDS-PAGE
resulted in a single band showing a molecular weight (MW) of
<14 KDa. The exact MW, as determined by mass spectrometry,
Figure 2. Chemical structures of the five DOP analogs chosen
for the in silico/in vitro analysis.
doi:10.1371/journal.pone.0009234.g002
Figure 1. Dopamine and the oxidation derivatives known to
interact with a-syn. (A) Protonated Dopamine (DOP-H), (B) Dopamine
(DOP), (C) Dopamine-o-quinone (DQ), (D) Dopaminochrome (DCH), (E)
5,6-Dihydroxyindole (DHI), (F) Indol-5,6-quinone (IQ).
doi:10.1371/journal.pone.0009234.g001
Table 1. a-syn binding of ligands in figures 1, 2 in
aqueous solution observed in MD simulations. DOP
and its oxidation derivatives abbreviations are explained in
detail in figure 1. Column titles from left to right: (i) ligand
name (ii) percentage of time in which the ligands are bound
to a-syn and (iii) to the
125YEMPS
129 ‘target’ region, (iv-v)
stabilizing electrostatic interaction energies between the
ligands and E83 and E61, two negatively charged residues of
the NAC region. Energy values of the force field are very
approximate
1 and do not take into account the screening of
the solvent. They should be taken here only for qualitative
comparisons. Here they are normalized with respect to the
most negative interaction energy between the neutral ligands
and the two negative residues (-2.8 kcal/mol, relative to the
interaction between IQ and E83). The DOPH/E61 energy turns
out to be very large in absolute value because the ligand is
charged, in contrast to all the others.
Ligand
%
protein
%
target
Point Charge
Model Av 6
Std (E83)
Point Charge
Model Av 6
Std (E61)
DOPH 70 32 0.0 214.9
DOP 69 46 0.0 20.7
DQ 49 28 20.3 20.3
DCH 72 32 20.8 20.5
DHI 91 16 0.0 0.0
IQ 62 32 21.0 20.3
6-aminoindole 68 23 0.0 0.0
Tyramine 48 19 0.0 0.1
4-(2-aminoethyl)
aniline
39 9 0.0 -0.2
5-hydroxyindole 70 23 -0.9 0.0
2-amino-4-tert-
butylphenol
62 19 0.0 0.0
1L. Guidoni, V. Torre and P. Carloni, FEBS Letters 477 (2000) 37-42.
doi:10.1371/journal.pone.0009234.t001
Modulated Alpha-Syn Aggregates
PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9234was 14459.4060.43 Da, and far-UV circular dichroism (CD)
measurements revealed a randomly coiled secondary structure.
Human a-syn was then used in the amyloid fibrillization
experiments in the presence and absence of the test ligands. For
each assay run, a concentration of 100 mMo fa-syn was used for
the synthesis of the fibrils. All ligands were added together with the
a-syn in an equimolar concentration at the start of the assay run.
Due to its known inhibitory effect on a-synuclein fibrilization,
dopamine was used as the control ligand [26]. Fibril formation was
achieved using a continuous in vitro fibrillization assay, with
amyloid fibril formation monitored by the dye, thioflavin T (ThT).
Each assay was always run in triplicate. The assays ran for
100 hours, continuously, under a controlled temperature of 37uC.
At the end of the assay, each sample revealed a kinetic curve
suggestive of amyloid fibril formation [35,36,37] comprising of a
lag phase, an exponential growth phase and an end plateau
(Figure 3A), which is typical of a nucleated polymerization type
process [38]. Moreover, there appeared to be no observable
significant differences in the average lag phase time between all
ligands (including dopamine) and a-syn alone (Figure 3B).
For all in vitro assays, the ligands and the control ligand DOP
were dissolved in a concentration of 0.1% dimethylsulfoxide
(DMSO). This concentration had been determined empirically by
a series of preliminary experiments set out to elucidate the
concentration where DMSO had no effect, upon both the lag
phase and the assembly of fibrils (see Figure S1, S2 and S3).
The continuous presence of ThT in the assay was assessed by
AFM, to determine whether this could have an effect upon the
aggregation of the protein and/or the binding of a ligand to the a-
syn. As DOP has previously been shown by AFM to inhibit the
aggregation of a-syn [26], the reaction of DOP with a-syn protein
in equimolar concentration in the assay, was assessed by AFM,
both in the presence and absence of the ThT dye. Neither the
presence nor the absence of ThT appeared to have any effect on
the inhibitory effect of DOP on the aggregation of a-syn (Figure 4).
AFM and TEM Analysis of the Ligands on the
Aggregation of a-Syn
Samples were analyzed by both AFM and TEM. In order to
detect any distinctive effect upon the assembly of the fibrils, we
developed a detailed classification of the fibrillar structures that had
been formed. Based on AFM analysis, fibrillar structures were
classified as follows: mature fibrils (.0.75 mm in length), interme-
diate fibrils (0.5–0.75 mm), short fibrils/fragments (or protofibrils)
(,0.5 mm). Qualitatively, AFM analysis revealed some differences
in terms of a-syn fibril assembly in the presence of the ligands
(Figure 5A–G).
The a-syn fibrils in the absence of any of the ligands consistently
revealed predominantly ‘mature’fibrils(<.0.75 mm inlength)with
an average width of <9.2 nm 62.2 nm on TEM micrographs (107
fibrils)(Figure4AandD,Figure5HandFigure6AandB,andFigure
S2 and Figure S3), in agreement with previous reports [39,40,41].
Moreover, they frequently appeared in clusters (Figure 4A and D,
Figure 6A and B, Figure S2 and Figure S3). In addition, round
spherical structures (possibly oligomers) were observed (Figure 5H
and Figure S2, Figure S3).
In the presence of the test ligands, in an equimolar concen-
tration with a-syn, the following observations were made. Overall,
whilst all ligands showed no complete inhibition on the assembly of
a-syn fibrils (Figure 5) compared to the control ligand DOP
(Figure 4), differences did appear in both fibril size and distribution
of particle aggregates (Figure 5A–G) when compared to a-syn alone
(Figure 4A and D, Figure 5H, Figure S2), which consistently
revealed mostly mature fibrils. DOP revealed no fibrils, and only
spherical structures (Figure 4B, C, E and F), whereas 5-hydro-
xyindole and 6-aminoindole revealed predominantly fibrils of an
intermediate and short size (Figure 5A, B, D, E). Tyramine and 2-
amino-4-tert-butylphenol revealed a mixture of both mature and
intermediate fibrils (Figure 5F and G), whereas 4-(2-aminoethylani-
line) revealed a mixture of all fibril sizes (Figure 5C). The ligand 6-
aminoindole appeared overall to show the greatest effect on the
assembly of a-syn fibrils. As MD simulations predicted that this
ligand and 5-hydroxyindole should have the strongest binding to a-
syn (Table 1), these two ligands were chosen for a more detailed
analysis by higher resolution with TEM.
By TEM, a-syn fibrils alone were generally observed in clusters
and longer than 0.75 mm in length (Figure 6A–B). In comparison,
6-aminoindole revealed individual structures, orientated in a
fibrillar form (Figure 6E–H), which at high magnification
suggested that these ‘fibrils’ could still be at an early/intermediate
stage of the fibrillization process. The ligand 5-hydroxyindole in
comparison showed clusters of a-syn fibrils, albeit shorter than a-
syn fibrils in the absence of this ligand (Figure 6C–D and
Figure 6A–B, respectively).
Figure 3. The kinetics of a-syn fibrillization with the DOP
analogs in comparison to a-syn alone. (A) Kinetics curves of a-syn
fibrillization in the presence of the test ligands. The fibrillization buffer
(i.e, no protein) was assayed in the absence of both a-syn and the test
ligands. All curves represent the mean kinetics output from at least 3
measurements. (B) Bar chart statistics displays no significant difference
between the lag phases.
doi:10.1371/journal.pone.0009234.g003
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PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9234Figure 4. AFM analysis of a-syn aggregation in the presence or absence of both ThT and DOP. AFM height images were acquired from
assay end products, which had been deposited onto freshly cleaved mica surfaces after 100 hours of incubation. The presence or absence of ThT
revealed no observable effect upon either the formation or morphology of a-syn fibrils when assay was run with a syn alone, (A) +ThT, (D)–ThT. The
inhibitory effect of DOP on the a syn fibrillization was clearly observed when the assay was run in the presence of DOP. (B, C, E, F). Moreover, the
presence (B, C) or absence (E, F) of ThT did not show any effect upon the inhibitory action of DOP on a-syn fibrillization.
doi:10.1371/journal.pone.0009234.g004
Figure 5. AFM analysis of a-syn aggregation in presence of test ligands as DOP analogs and alone. AFM height images were acquired
from assay end products, which had been deposited onto freshly cleaved mica surfaces after 100 hours of incubation. All images are displayed using
the same color scale as shown on the right hand side. (A–B) 5-hydroxyindole; (C) 4-(2-aminoethyl)aniline; (D-E) 6-aminoindole; (F) 2-amino-4-tert-
butylphenol; (G) tyramine; (H) a-syn only.
doi:10.1371/journal.pone.0009234.g005
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The loss of dopaminergic neurons in the substantia nigra and the
presence of a-syn containing Lewy bodies are the classical diagnostic
markers of PD. DOPhas beenshownto inhibita-synaggregation by
binding to the a-syn protein [21,22,23,24,25,26,27,29]. Thus, DOP
mimics might have some effect on the aggregation of the protein.
We analyzed this issue using a combined in silico and in vitro
approach. Ligand screening and molecular docking allowed us to
identify the five commercially available ligands used in this study,
which are structurally and electrostatically similar to DOP
(Figure 2). Thus, we predicted that these ligands might have a
weaker inhibitory effect on fibrillization than DOP.
To test our predictions, we developed a continuous in vitro
fibrillization assay. We observed the kinetics of the fibrillization
process and analyzed the reaction end products by AFM to obtain
spatially resolved information of their morphology. AFM revealed
that the ligands caused some inhibitory effect, albeit weaker than
that of DOP (Figure 5 and Figure 4 respectively). Moreover, it was
clearly apparent that the fibrillar structures varied in terms of their
length and in the population distribution of the structures for each
test ligand (Figure 5), although the kinetic data were typical of an
occurring nucleation/polymerization mechanism (Figure 3A).
Likewise, the kinetics curves for each ligand did vary in terms of
exponential growth time and plateau phases (Figure 3A). The
ligand 6-aminoindole revealed the strongest inhibitory effect upon
fibril formation, which was consistent with the fact that it binds
most strongly (along with 5-hydroxindole) to the
125YEMPS
129
‘target’ region (Table 1). In comparison, 4-(2-aminoethyalinine)
showed the weakest effect (Figure 5), consistent with our MD data
(Table 1).
Whilst all the ligands used in our study share the same chemical
scaffolding, we noticed (as revealed by both the kinetic output
curve and AFM analysis) the strength of DOP in inhibiting a-syn
fibril formation in comparison to the tested ligands, especially
tyramine (Figure 3); which was consistent with our modeling
(Table 1). Tyramine differs from DOP only by a hydrogen in place
of a hydroxyl group. The removal of the polar OH function is
associated with a loss of electrostatic interactions with the two
negatively charged groups of the NAC region. We thus propose
that the dihydroxyphenyl group (or 1,2 benzoquinone as in some
dopamine derivatives, like dopaminochrome) may play an
important role for binding to a-syn, possibly through long-range
electrostatic interactions. Moreover, based on these considerations,
we suggest that ligands with dihydroxyphenyl (or 1,2 benzoqui-
none) groups could be selected for further non-covalent binding
assays.
Indoles are compounds that are known to interact with metal
ions, which themselves are known to increase in PD brains [42].
Furthermore, metal ions are known to bind to, and facilitate, the
aggregation of a-syn [42,43]. Whilst we cannot exclude the
presence of metal ions in our assay, we nevertheless ensured that
the highest-grade analytical chemicals with the minimal presence
of metal ions were always used.
Interestingly, the ultra-structural analysis of a-syn in the
presence of 6-aminoindole not only showed fibrils more isolated
and shorter than just a-syn alone (Figure 6A–B), but at a higher
resolution it was possible to clearly identify that the process of
‘fibril’ developing into a mature fibril assembly had been affected
by the ligand, when compared to a-syn alone (Figure 6A compared
to 6H). Most importantly, the kinetic data for both a-syn with this
ligand, and a-syn alone, revealed similar ThT fluorescence with
the characteristic growth curve. Therefore, we only used ThT
fluorescence as a monitor of amyloid fibril formation. A more
detailed quantitative methodology of classification would aid to
verify our observations. This is currently under development.
Our conclusions, drawn from the ultra-structural analysis of
aggregated a-syn in the presence of 6-aminoindole, are further
supported by a recent study by Tashiro et al. [44], which
characterized over 76 hours of the fibrillization process of a-syn
by electron microscopy and small angle x-ray scattering. The
authors observed the progression of the formation of fibrils to a
mature form using a discontinuous fibrillization assay. Whilst they
clearly saw mature fibrils formed at 60 hours, our images at
100 hours for 6-aminoindole did not show this stage of formation
(Fure 6E–H). Our TEM images for 6-aminoindole (Figure 6E–H
and unpublished data) obtained at the end of the assay (i.e.:
Figure 6. TEM micrographs showing the effect of the
presence of 6-aminoindole or 5-hydroxindole on the aggre-
gation of a-syn. Whilst both samples revealed similar kinetic data,
typical of a nucleation/polymerization process, microscopy revealed
contrasting data. (A and B) a-syn fibrils formed in the absence of any
ligands, (C and D) a-syn fibrils formed in the presence of 5-
hydroxyindole and (E–H) 6-aminoindole. Arrows indicate fibrillar
structures of varying size.
doi:10.1371/journal.pone.0009234.g006
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aggregation of a-syn at 33 hours, which, they speculated, could
have been fibrils forming via a critical nucleus or soluble
oligomers. Most importantly, their study clearly supports our
implication that 6-aminoindole does indeed affect the nucleation/
polymerization mechanism. Whilst the main aim of our study was
to use in vitro assays to test our prediction of DOP mimics on a-syn,
it is clear that a detailed high resolution study over more time
points would lead to a deeper insight into the mechanism of the
observed DOP mimics on the aggregation of a-syn.
In conclusion, the combined in silico and in vitro approach
employed here is, to our knowledge, the first study where such a
detailed approach has been used to predict and evaluate ligands
that may affect the aggregation of a-syn by forming non-covalent
interactions. Biocomputational methods screened and predicted
ligands that could have some inhibitory effect on the aggregation
of a-syn protein. Remarkably, in vitro assays in combination with
high-resolution microscopy showed similar findings. The consis-
tency between both approaches highlights the importance of a
combined in silico and in vitro approach that could be used in
predicting and developing new drugs and therapeutic strategies for
PD.
Materials and Methods
Biocomputing of a-Syn Structures
A refined set of structures, obtained with an optimized protocol,
was kindly provided by M. Vendruscolo (personal communica-
tion). A cluster analysis was performed exactly as previously
reported [29]. Six representative structures were identified [29].
Biocomputing of Ligands
(i) The structures of dopamine and its oxidation products
(Figure 1 in [29]) were taken from a previous publication [23].
(ii) Ligands similar to DOP and to its oxidative derivatives
(Figure 1) were identified by virtual screening of the ‘ligand.info’
database [31]. This database contains <1,160,000 ligands.
Structural similarity was estimated by the Tanimoto’s equation
[32] using the ROCS algorithm in the OpenEye suite of programs
(http://www.openeye.org). The 3D molecular structures were
overlapped using atom-centered Gaussians [45]. A bias on the
overlay was achieved by adding a positive weight to similar
chemical groups. For each template, the 100 best hits were
selected (600 molecules overall).
The similarity in electrostatic potential between the selected
molecules and their templates in Figure 1 was then calculated
using the Tanimoto metric [32]. The EON module of Openeye
was used (See Supporting Information S1) [46]. The top 10 hits
for each template (60 ligands overall) were docked onto 6 a-syn
representative conformations of the protein NMR conforma-
tional ensemble; the same procedure as described previously by
Herrera et al. [29]. The adducts were ranked based on the
number of contacts [29] between the target region
125YEMPS
129
[23,25,27] and the ligand. Five commercially available ligands
forming top ranking adducts were selected for experimental
analysis (Figure 2).
MD Simulations of Ligands (i) and (ii) to a-Syn
All of the adducts, with all the five ligands, underwent 6 ns of
MD in explicit solvent, as previously reported [29]. Version 2.6 of
the NAMD program was used [47]. Overall, 72 different MD
simulations were carried out. We identify as bound complexes the
adducts in which the distance between Ca of a-syn and ligands
center of mass is lower than 8 A ˚.
Expression, Purification and Characterization of
Recombinant Human a-Syn
All chemicals used for the experimental assays were high-
grade analytical chemicals .99.9% purity with minimal metal
impurities.
Human a-syn nucleotide sequence was cloned into the pET11a
expression vector and introduced into E. coli strain BL21 (DE3).
Expression of a-syn was obtained by growing cells in 100 mg/mL
ampicillin containing Luria-Bertani broth at 37uC until an OD600
of about 0.6, followed by induction with 0.6 mM isopropyl b-
thiogalactopyranoside for 5 hours. The protein was purified, based
on the method of Huang et al. [34].
Mass Spectrometry
The exact molecularweight of the purified a-syn wasanalyzed by
reverse phase high performance liquid chromatography (HPLC)
followed by mass spectrometry. Reverse phase HPLC was carried
out using a C4 Phenomenex Jupiter (15064.6 mm) and eluted with
a gradient of acetonitrile and trifluoroacetic acid (TFA) 0.085%
versus water and 0.1% TFA: from 5 to 35% over 5 min, from 35
to 55% over 20 min, from 55 to 95% over 2 min, at a flow rate
of 0.6 mL/min. The effluent from the column was monitored by
recording absorbance at 226 nm wavelength. The eluted peak was
collected and analyzed by mass spectrometry using a Mariner
System 5220 (Applied Biosystem) spectrometer. Mass measure-
ments were carried out in collaboration with Dr. P. De Laureto
(C.R.I.B.I., University of Padua, Italy).
Circular Dichroism (CD) Spectroscopy
CD measurements were carried out on a JASCO J-810
spectrophotometer. Spectra were acquired at room temperature
in Tris-HCl 20 mM, pH 8.0 using a HELLMA quartz cell (Cell
Bio), with an optical path-length of 0.1 cm. All spectra were
recorded in the 196–250 nm wavelength range, using a bandwidth
of 1 nm and a time constant of 1 s at a speed of 20 nm/min. The
signal-to-noise ratio was improved by accumulating 4 scans.
Preparation of a-Syn Solutions and Dopamine Analogs
for the In Vitro Studies
The solutions for the in vitro assay were prepared as follows. All
solutions were sterile, filtered through a 0.22 mm filter prior to
each assay run in order to reduce the presence of ‘contaminants’.
Lyophilized a-syn was dissolved in 20 mM Tris-HCl/150 mM
NaCl/pH 7.4 (i.e.: the fibrillization buffer) to achieve a stock
concentration of 3 mg/mL. All 5 test ligands (Figure 2) and
dopamine were dissolved in DMSO, to achieve a final stock
concentration of 10 mM. The ligands and a-syn were then both
diluted with the fibrillization buffer, to equimolar concentrations
(100 mM) in a final DMSO concentration of 0.1%. Amyloid fibril
formation was monitored with the histological dye, ThT. A total of
10 mM ThT was added to each sample. Final working volumes
were 200 mL per well. Fibril formation was monitored on either a
GEMINI EM plate reader or a Spectramax M5 (Molecular
Devices). Each test ligand with a-syn was run in triplicate, in 96
black well plates; each well containing 1 teflon bead. The plate was
incubated at 37uC, shaken, and ThT fluorescence readings were
recorded every 5 min till 100 hours. For each assay run, the
background fluorescence from each ligand (i.e. in the absence of
a-syn) was also recorded and run in triplicate.
AFM Analysis
The assay end product was imaged with a NanoWizard-II
BioAFM (JPK Instruments AG) operating in dynamic mode.
Modulated Alpha-Syn Aggregates
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TM silicon probe with Al
coating at the detector side, a tip radius ,10 nm, a nominal spring
constant of 42 N/m and a nominal resonance frequency of
285 kHz (NanoWorld). Fibrils were deposited onto a freshly
cleaved piece of mica at a concentration of 15 mM and left to
adhere for 60 min. Samples were then washed with distilled water
and blow-dried under a flow of nitrogen. Optically clear regions
were chosen for the scanning analysis. The images were collected
at a line scan rate of 0.5 - 2 Hz in ambient conditions. The AFM
free oscillation amplitudes were ranging from 25 nm to 40 nm,
with characteristic set points ranging from 75% to 90% of these
free oscillation amplitudes.
TEM Analysis
The assay end product was analyzed on a Jeol 2010F UHR
TEM/STEM microscope operated at an accelerating voltage of
200 kV. Samples were absorbed to 300 mm holey formvar/carbon
coated grids for <1 minute before a brief rinse in water, and
negatively stained for 1 minute with 1% phosphotungstic acid.
Typical magnifications ranged from 20000-180000.
Image Analysis of AFM Scans and TEM Micrographs
AFM data were analyzed with Gwyddion (gwyddion.net) and
SPIP
TM, (www.imagemet.com). TEM images were analyzed,
using the NIH Image processing program, Image J (rsbweb.nih.
gov/ij/).
Supporting Information
Supporting Information S1 Supporting information manu-
script including references.
Found at: doi:10.1371/journal.pone.0009234.s001 (0.04 MB
DOC)
Table S1 Molecules selected from the ligand.info database. Ten
molecules have been selected for each of the six compounds
reported in Figure 1. These are the molecules which feature the
largest shape and electrostatic similarity with dopamine, as
calculated using the Tanimoto’s definition. The compounds for
each set are listed in the order of the priority score. Five
commercially available ligands among these 60 molecules have
undergone the in vitro assay reported in this study. They are
highlighted in bold.
Found at: doi:10.1371/journal.pone.0009234.s002 (0.06 MB
DOC)
Table S2 Hydrogen bonds and hydrophobic contacts between
the ligands (as depicted in Figure 2) or the dopamine oxidation
products (Figure 1) and the target region of a-syn conforma-
tions. Column titles from left to right: (i) number of the
representative conformation of a-syn, (ii) ligand name, (iii)
hydrogen-bonds and distances, (iv) hydrophobic contacts and
distances. The contacts are listed for the adducts where the
ligands are bound to the target region for more than 50% of
their time. Highlighted in grey are the compounds used in the
experiments.
Found at: doi:10.1371/journal.pone.0009234.s003 (0.10 MB
DOC)
Table S3 Binding regions of ligands other than the target region.
Column titles from left to right: (i) The representative conforma-
tion of a-syn, (ii) ligand name, (iii) binding region. The contacts are
listed for those adducts in which the ligands bind to regions other
than the target region for more than 50% of their time.
Highlighted in grey are the compounds used in the experiments.
Found at: doi:10.1371/journal.pone.0009234.s004 (0.05 MB
DOC)
Figure S1 The average lag phase time of I ˆ6-syn aggregation in
different concentrations of DMSO. Notice that above 2.5%
DMSO concentration, the lag phase time becomes extremely
variable.
Found at: doi:10.1371/journal.pone.0009234.s005 (0.45 MB TIF)
Figure S2 AFM images of the aggregation of I ˆ6-syn. AFM
height images were acquired from assay end products after
100 hours of incubation which had been deposited onto freshly
cleaved mica surfaces. The height images (A, B, D) are displayed
using the same color scale as shown on the right hand side. (A)
Height image of long straight fibrils with occasional ‘putative’
looking oligomers. (B) Height image and (C) phase image (range
0–13 deg) of a cluster of fibrils. (D) Height image showing a high
degree of clustering of fibrils.
Found at: doi:10.1371/journal.pone.0009234.s006 (3.15 MB TIF)
Figure S3 AFM images of the aggregation of I ˆ6-syn in 0.1%
DMSO. AFM height images were acquired from assay end
products after 100 hours of incubation which had been deposited
onto freshly cleaved mica surfaces. The height images (A, C, D)
are displayed using the same color scale as shown on the right
hand side. (A) Height image and (B) phase image (range: 0–40 deg)
of long straight fibrils with branching. (C–D) Height images of
long, straight and circular fibrils, fragments, and both clustered
and scattered ‘putative’ oligomers.
Found at: doi:10.1371/journal.pone.0009234.s007 (3.18 MB TIF)
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